US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elicio Therapeutics

5.41

-0.3000-5.25%

Volume:33.83K

Turnover:190.53K

Market Cap:86.23M

PE:-1.27

High:5.82

Open:5.75

Low:5.34

Close:5.71

Loading ...

Overview Company News Filings

Elicio Therapeutics Hires CFO From Cidara Therapeutics

Elicio Therapeutics Appoints Preetam Shah, Ph.d., MBA, as Chief Strategy and Financial Officer

THOMSON REUTERS

Press Release: Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Elicio Therapeutics Inc - Offering Closing Expected on or About January 30, 2025

THOMSON REUTERS

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Elicio Therapeutics Advances with New Clinical Updates

JonesTrading Reaffirms Their Buy Rating on Elicio Therapeutics (ELTX)

Elicio reaches alignment with FDA on ELI-002 registrational strategy

Elicio Therapeutics: Phase 2 Randomized Study of Eli-002 Fully Enrolled, With Formal Interim Analysis of Disease-Free Survival Expected in H1 2025

THOMSON REUTERS

Elicio Therapeutics Reaches Alignment With FDA on Eli-002 Registrational Strategy

THOMSON REUTERS

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)

Elicio Therapeutics Advances ELI-002 and Secures Funding

Elicio Therapeutics presents updated results from ELI-002 Phase 1 study

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics announces completion of Phase 2 AMPLIFY-7P study enrollment

Elicio Therapeutics Announces Completion of Phase 2 Amplify-7P Study Enrollment

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ELTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":5.41,"timestamp":1747252800000,"preClose":5.71,"halted":0,"volume":33830,"delay":0,"floatShares":10268391,"shares":15939069,"eps":-4.25289,"marketStatus":"Post-Mkt","change":-0.3,"latestTime":"05-14 19:06:25 EDT","open":5.75,"high":5.82,"low":5.34,"amount":190531.9062,"amplitude":0.084063,"askPrice":5.8,"askSize":200,"bidPrice":2.17,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-4.25289,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1747267200000},"marketStatusCode":4,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":5.71,"volumeRatio":1.206207,"impliedVol":0.6041,"impliedVolPercentile":0.7},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","floatShares":10268391,"roa":"-101.64%","roe":"-170157.38%","lyrEps":-4.25289,"volumeRatio":1.206207,"shares":15939069,"dividePrice":0,"high":5.82,"amplitude":0.084063,"preClose":5.71,"low":5.34,"week52Low":3.3419,"pbRate":"-7.62","week52High":11.45,"institutionHeld":0,"latestPrice":5.41,"eps":-4.25289,"divideRate":0,"volume":33830,"delay":0,"ttmEps":-4.25289,"open":5.75,"prevYearClose":5.1,"prevWeekClose":5.49,"prevMonthClose":4.92,"prevQuarterClose":6.16,"fiveDayClose":4.96,"twentyDayClose":4.98,"sixtyDayClose":8.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521974283","title":"Elicio Therapeutics Hires CFO From Cidara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2521974283","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521974283?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:46","pubTimestamp":1742816760,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics has hired the former chief financial officer of Cidara Therapeutics to lead its strategy and finances.The Boston-based Elicio said Monday that Preetam Shah has been appointed chief strategy and financial officer.Shah will also serve as the biotechnology company's principal financial officer and principal accounting officer.He most recently served as the chief financial officer and chief business officer of fellow biotech Cidara. Before that, Shah was the CFO for Brainstorm Cell Therapeutics and has held roles at Barclays Capital and Canaccord Genuity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","CDTX"],"gpt_icon":0},{"id":"2521746826","title":"Elicio Therapeutics Appoints Preetam Shah, Ph.d., MBA, as Chief Strategy and Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746826?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:02","pubTimestamp":1742814165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q715W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0},{"id":"2521745616","title":"Press Release: Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745616","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745616?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"BOSTON, March 24, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies.\"We are pleased to welcome Preetam to Elicio's executive team,\" said Robert Connelly, Ph.D., President and Chief Executive Officer of Elicio. \"He joins us during an exciting time. We remain encouraged by the potential of ELI-002 and the broad applicability of the Amphiphile platform, and I am confident that Preetam's extensive experience in corporate finance, strategy, and business development will be a tremendous asset to our Company.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2519803924","title":"With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2519803924","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519803924?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:51","pubTimestamp":1741949494,"startTime":"0","endTime":"0","summary":"Significant insider control over Elicio Therapeutics implies vested interests in company growth. The largest shareholder of the company is Yekaterina Chudnovsky with a 50% stake. Past performance of a company along with ownership data serve to give a strong idea about prospects for a business. If you want to know who really controls Elicio Therapeutics, Inc. , then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 36% to be precise, is individual insiders. Put another way, the group faces the maximum upside potential .So, insiders of Elicio Therapeutics have a lot at stake and every decision they make on the company’s future is important to them from a financial point of view.Let's delve deeper into each type of owner of Elicio Therapeutics, beginning with the chart below.The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/36-ownership-elicio-therapeutics-inc-105134606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","SQQQ","ELTX","IE00B64PRP62.GBP","MNQmain","BK4139","TQQQ","IE00BKPKM429.USD","QLD","LU2210150020.SGD","BK4588",".IXIC","BK4585","USJW.SI","NVIW.SI","USAW.SI","BK4112","QID","NDAQ","LU2210149790.SGD","NQmain","TSYW.SI","BK4007","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","PSQ"],"gpt_icon":1},{"id":"2517319372","title":"Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517319372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517319372?lang=en_us&edition=fundamental","pubTime":"2025-03-07 01:20","pubTimestamp":1741281636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE – Research Report), ALX Onco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","ALX","FATE","HCSG","BK4137","ALXO","ELTX","BK4007","BK4231","BK4139"],"gpt_icon":0},{"id":"2507279640","title":"Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2507279640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507279640?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA4CZBSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2507164073","title":"Elicio Therapeutics Inc - Offering Closing Expected on or About January 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507164073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507164073?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA4CZBSP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2507400876","title":"Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2507400876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507400876?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242000,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 30, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional investors for the purchase of an aggregate of 1,261,830 shares of its common stock and accompanying warrants to purchase up to an aggregate of 1,261,830 shares of its common stock, at a purchase price of $7.925 per share and accompanying warrant in a registered direct offering  priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $7.80 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date. The closing of the Offering is expected to occur on or about January 30, 2025, subject to the satisfaction of customary closing conditions.The aggregate gross proceeds to the Company from the Offering are expected to be approximately $10.0 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elicio-therapeutics-announces-10-0-130000704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","BK4588","BK4139","NVIW.SI","USJW.SI","IE00B64PRP62.GBP","BK4007","QID","TQQQ","MNQmain","IE00BGHQF748.EUR","LU2210149790.SGD","BK4585",".IXIC","TSYW.SI","IE00B3QW5Z07.USD","BK4112","NDAQ","NQmain","LU2210150020.SGD","ELTX","LU2095319765.USD","SQQQ","USAW.SI","IE00BKPKM429.USD","QLD"],"gpt_icon":1},{"id":"2505024798","title":"Elicio Therapeutics Advances with New Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2505024798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505024798?lang=en_us&edition=fundamental","pubTime":"2025-01-24 06:01","pubTimestamp":1737669716,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics ( ($ELTX) ) has issued an announcement. On January 23, 2025, Elicio Therapeutics announced the addition of a corporate presenta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/elicio-therapeutics-advances-with-new-clinical-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/elicio-therapeutics-advances-with-new-clinical-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2505740777","title":"JonesTrading Reaffirms Their Buy Rating on Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505740777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505740777?lang=en_us&edition=fundamental","pubTime":"2025-01-23 02:45","pubTimestamp":1737571510,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Elicio Therapeutics (ELTX – Research Report). The company’s sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX"],"gpt_icon":0},{"id":"2505741209","title":"Elicio reaches alignment with FDA on ELI-002 registrational strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2505741209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505741209?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:41","pubTimestamp":1737549665,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) announced that it has received supportive feedback in an End of Phase 1 Type B meeting with the U.S. Food and Drug Admin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-reaches-alignment-with-fda-on-eli-002-registrational-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-reaches-alignment-with-fda-on-eli-002-registrational-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0},{"id":"2505491067","title":"Elicio Therapeutics: Phase 2 Randomized Study of Eli-002 Fully Enrolled, With Formal Interim Analysis of Disease-Free Survival Expected in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505491067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505491067?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:30","pubTimestamp":1737549004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI0PI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2505474910","title":"Elicio Therapeutics Reaches Alignment With FDA on Eli-002 Registrational Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2505474910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505474910?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:30","pubTimestamp":1737549004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI0PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2505749034","title":"Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2505749034","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505749034?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:30","pubTimestamp":1737549000,"startTime":"0","endTime":"0","summary":"Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis Phase 2 randomized study of E","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/22/3013378/0/en/Elicio-Therapeutics-Reaches-Alignment-with-FDA-on-ELI-002-Registrational-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2490849953","title":"JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490849953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490849953?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:35","pubTimestamp":1734014119,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Elicio Therapeutics (ELTX – Research Report). The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX"],"gpt_icon":0},{"id":"2490780724","title":"Elicio Therapeutics Advances ELI-002 and Secures Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2490780724","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490780724?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:29","pubTimestamp":1734006565,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics ( ($ELTX) ) has issued an announcement. Elicio Therapeutics has announced updated results from its ELI-002 Phase 1 AMPLIFY-201 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/elicio-therapeutics-advances-eli-002-and-secures-funding?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/elicio-therapeutics-advances-eli-002-and-secures-funding?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2490802257","title":"Elicio Therapeutics presents updated results from ELI-002 Phase 1 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490802257","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490802257?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:11","pubTimestamp":1734005475,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) presented updated results from the Phase 1 AMPLIFY-201 clinical trial of ELI-002, an Amphiphile, AMP, cancer vaccine tha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-presents-updated-results-from-eli-002-phase-1-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-presents-updated-results-from-eli-002-phase-1-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ELTX"],"gpt_icon":0},{"id":"2490802983","title":"Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490802983","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490802983?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:00","pubTimestamp":1734004800,"startTime":"0","endTime":"0","summary":"Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study population Strong correlation observed between mRFS an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996042/0/en/Elicio-Therapeutics-Presents-Updated-Results-from-ELI-002-Phase-1-AMPLIFY-201-Study-at-ESMO-Immuno-Oncology-Congress-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2488991986","title":"Elicio Therapeutics announces completion of Phase 2 AMPLIFY-7P study enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2488991986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488991986?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:05","pubTimestamp":1733227511,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) announced the completion of enrollment in the Phase 2 AMPLIFY-7P study. The randomized Phase 2 study is evaluating a 7-p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-announces-completion-of-phase-2-amplify-7p-study-enrollment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-announces-completion-of-phase-2-amplify-7p-study-enrollment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2488157039","title":"Elicio Therapeutics Announces Completion of Phase 2 Amplify-7P Study Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2488157039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488157039?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA5NF3SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ELTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"ELTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.87},{"market":"US","date":"2025-03-31","symbol":"ELTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2024-11-13","symbol":"ELTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.81,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2024-08-13","symbol":"ELTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.96,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2024-05-15","symbol":"ELTX","fiscalQuarterEnding":"2024/03","expectedEps":-1.09,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELTX","date":"2025-05-13","current":-1.695319,"percent":0.477169,"low":-9.235249,"twenty":-2.588663,"median":-1.632359,"eighty":-1.235702,"high":-0.963611,"avg":-1.949347,"sd":1.017108,"marketCap":87983660},"quantilePoints":[{"date":"2023-06-09","current":-9.235249,"twenty":-9.235249,"median":-9.19865,"eighty":-8.861936,"marketCap":260505032},{"date":"2023-06-16","current":-4.797096,"twenty":-9.19133,"median":-5.471097,"eighty":-5.286091,"marketCap":135315000},{"date":"2023-06-23","current":-3.669177,"twenty":-9.011993,"median":-5.35246,"eighty":-4.343178,"marketCap":103499000},{"date":"2023-06-30","current":-3.232452,"twenty":-8.711878,"median":-5.281964,"eighty":-3.931212,"marketCap":91180000},{"date":"2023-07-07","current":-3.782657,"twenty":-7.82363,"median":-4.797096,"eighty":-3.594899,"marketCap":106700000},{"date":"2023-07-14","current":-3.799851,"twenty":-5.457342,"median":-4.009616,"eighty":-3.669177,"marketCap":107185000},{"date":"2023-07-21","current":-3.868626,"twenty":-5.416077,"median":-3.868626,"eighty":-3.616907,"marketCap":109125000},{"date":"2023-07-28","current":-3.026831,"twenty":-5.342487,"median":-3.782657,"eighty":-3.314983,"marketCap":85379914},{"date":"2023-08-04","current":-2.958445,"twenty":-5.286091,"median":-3.758585,"eighty":-2.99472,"marketCap":83450898},{"date":"2023-08-11","current":-2.973312,"twenty":-5.075638,"median":-3.643386,"eighty":-2.969744,"marketCap":83870250},{"date":"2023-08-18","current":-2.842099,"twenty":-4.570137,"median":-3.57633,"eighty":-2.953093,"marketCap":83656289},{"date":"2023-08-25","current":-2.726636,"twenty":-4.18018,"median":-3.222136,"eighty":-2.868421,"marketCap":79553028},{"date":"2023-09-01","current":-2.370739,"twenty":-4.067388,"median":-3.000071,"eighty":-2.849368,"marketCap":69169264},{"date":"2023-09-07","current":-2.433882,"twenty":-3.951844,"median":-2.973312,"eighty":-2.844375,"marketCap":71011545},{"date":"2023-09-15","current":-2.413791,"twenty":-3.886508,"median":-2.973312,"eighty":-2.761879,"marketCap":70425365},{"date":"2023-09-22","current":-2.293245,"twenty":-3.841116,"median":-2.967365,"eighty":-2.647421,"marketCap":66908283},{"date":"2023-09-29","current":-2.413791,"twenty":-3.792973,"median":-2.953985,"eighty":-2.537207,"marketCap":70425365},{"date":"2023-10-04","current":-2.276024,"twenty":-3.782657,"median":-2.940605,"eighty":-2.474064,"marketCap":66405843},{"date":"2023-10-10","current":-2.098075,"twenty":-3.781281,"median":-2.875192,"eighty":-2.428715,"marketCap":61213961},{"date":"2023-10-19","current":-2.009101,"twenty":-3.779218,"median":-2.868708,"eighty":-2.413791,"marketCap":58618021},{"date":"2023-10-27","current":-1.922996,"twenty":-3.775091,"median":-2.867273,"eighty":-2.413791,"marketCap":56105820},{"date":"2023-11-03","current":-1.871334,"twenty":-3.740703,"median":-2.849368,"eighty":-2.290949,"marketCap":54598499},{"date":"2023-11-10","current":-1.690515,"twenty":-3.669177,"median":-2.844944,"eighty":-2.243878,"marketCap":49322877},{"date":"2023-11-17","current":-1.533738,"twenty":-3.658861,"median":-2.768921,"eighty":-2.084298,"marketCap":50453368},{"date":"2023-11-24","current":-1.527374,"twenty":-3.617595,"median":-2.739552,"eighty":-1.974659,"marketCap":50244018},{"date":"2023-12-01","current":-1.565558,"twenty":-3.614157,"median":-2.617571,"eighty":-1.90147,"marketCap":51500118},{"date":"2023-12-08","current":-1.48919,"twenty":-3.583895,"median":-2.583129,"eighty":-1.87076,"marketCap":48987917},{"date":"2023-12-15","current":-1.540102,"twenty":-3.452534,"median":-2.531467,"eighty":-1.708711,"marketCap":50662718},{"date":"2023-12-22","current":-1.476462,"twenty":-3.314983,"median":-2.474064,"eighty":-1.60527,"marketCap":48569217},{"date":"2023-12-29","current":-2.102685,"twenty":-3.232452,"median":-2.429577,"eighty":-1.641927,"marketCap":69169264},{"date":"2024-01-05","current":-2.03949,"twenty":-3.220072,"median":-2.413791,"eighty":-1.611379,"marketCap":67090423},{"date":"2024-01-12","current":-1.576818,"twenty":-3.100826,"median":-2.392265,"eighty":-1.585578,"marketCap":51870515},{"date":"2024-01-19","current":-1.427896,"twenty":-3.005423,"median":-2.30616,"eighty":-1.564031,"marketCap":46971633},{"date":"2024-01-26","current":-1.124213,"twenty":-2.973312,"median":-2.283466,"eighty":-1.540772,"marketCap":36981756},{"date":"2024-02-02","current":-1.314015,"twenty":-2.973312,"median":-2.260238,"eighty":-1.528392,"marketCap":43225429},{"date":"2024-02-09","current":-1.226414,"twenty":-2.973312,"median":-2.227231,"eighty":-1.508027,"marketCap":40343734},{"date":"2024-02-16","current":-1.220574,"twenty":-2.970933,"median":-2.10038,"eighty":-1.496317,"marketCap":40151621},{"date":"2024-02-23","current":-1.170933,"twenty":-2.967365,"median":-2.077039,"eighty":-1.484607,"marketCap":38518660},{"date":"2024-03-01","current":-1.185534,"twenty":-2.965581,"median":-2.037802,"eighty":-1.427936,"marketCap":38998943},{"date":"2024-03-08","current":-1.305255,"twenty":-2.958445,"median":-1.951697,"eighty":-1.350807,"marketCap":42937259},{"date":"2024-03-15","current":-1.530098,"twenty":-2.956661,"median":-1.917256,"eighty":-1.360152,"marketCap":50333611},{"date":"2024-03-22","current":-1.927222,"twenty":-2.947741,"median":-1.909363,"eighty":-1.380707,"marketCap":63397296},{"date":"2024-03-28","current":-2.178345,"twenty":-2.940605,"median":-1.925109,"eighty":-1.425549,"marketCap":71658156},{"date":"2024-04-05","current":-2.18389,"twenty":-2.875192,"median":-1.928736,"eighty":-1.427896,"marketCap":76862025},{"date":"2024-04-12","current":-2.872164,"twenty":-2.872164,"median":-2.000282,"eighty":-1.428095,"marketCap":101085828},{"date":"2024-04-19","current":-2.390082,"twenty":-2.870144,"median":-2.037802,"eighty":-1.436656,"marketCap":84118945},{"date":"2024-04-26","current":-2.64274,"twenty":-2.867273,"median":-2.070475,"eighty":-1.460017,"marketCap":93011227},{"date":"2024-05-03","current":-2.613699,"twenty":-2.860548,"median":-2.080854,"eighty":-1.476462,"marketCap":91989126},{"date":"2024-05-10","current":-2.758904,"twenty":-2.852923,"median":-2.121507,"eighty":-1.483377,"marketCap":97099633},{"date":"2024-05-17","current":-2.458726,"twenty":-2.860548,"median":-2.154849,"eighty":-1.484098,"marketCap":95873111},{"date":"2024-05-24","current":-2.3198,"twenty":-2.852923,"median":-2.20556,"eighty":-1.486644,"marketCap":90455973},{"date":"2024-05-31","current":-1.968554,"twenty":-2.850079,"median":-2.181118,"eighty":-1.488681,"marketCap":76759815},{"date":"2024-06-07","current":-2.125179,"twenty":-2.849368,"median":-2.152608,"eighty":-1.489212,"marketCap":82867106},{"date":"2024-06-14","current":-2.233016,"twenty":-2.846714,"median":-2.152608,"eighty":-1.492255,"marketCap":87071996},{"date":"2024-06-21","current":-1.741174,"twenty":-2.844944,"median":-2.140329,"eighty":-1.496317,"marketCap":67893594},{"date":"2024-06-28","current":-1.812189,"twenty":-2.844944,"median":-2.140329,"eighty":-1.498354,"marketCap":70662668},{"date":"2024-07-05","current":-0.967903,"twenty":-2.843237,"median":-2.110101,"eighty":-1.488172,"marketCap":37741454},{"date":"2024-07-12","current":-1.249432,"twenty":-2.834001,"median":-2.100781,"eighty":-1.469884,"marketCap":48719089},{"date":"2024-07-15","current":-1.260464,"twenty":-2.831302,"median":-2.098877,"eighty":-1.455345,"marketCap":49149280},{"date":"2024-08-02","current":-1.401267,"twenty":-2.828603,"median":-2.098877,"eighty":-1.436656,"marketCap":54639616},{"date":"2024-08-09","current":-1.290931,"twenty":-2.802466,"median":-2.080854,"eighty":-1.401267,"marketCap":50337284},{"date":"2024-08-16","current":-1.201045,"twenty":-2.796658,"median":-2.072003,"eighty":-1.349055,"marketCap":46438413},{"date":"2024-08-23","current":-1.241178,"twenty":-2.769689,"median":-2.062918,"eighty":-1.296495,"marketCap":47990130},{"date":"2024-08-30","current":-1.113164,"twenty":-2.768153,"median":-2.038646,"eighty":-1.281895,"marketCap":43040476},{"date":"2024-09-06","current":-1.110381,"twenty":-2.760754,"median":-2.011962,"eighty":-1.261256,"marketCap":42932874},{"date":"2024-09-13","current":-1.132616,"twenty":-2.753755,"median":-1.991463,"eighty":-1.24953,"marketCap":43792608},{"date":"2024-09-20","current":-1.430415,"twenty":-2.736707,"median":-1.971607,"eighty":-1.23844,"marketCap":55307011},{"date":"2024-09-27","current":-1.355277,"twenty":-2.727862,"median":-1.927222,"eighty":-1.247781,"marketCap":52401779},{"date":"2024-10-04","current":-1.35806,"twenty":-2.717602,"median":-1.920126,"eighty":-1.24953,"marketCap":52509380},{"date":"2024-10-11","current":-1.333014,"twenty":-2.703726,"median":-1.89225,"eighty":-1.251663,"marketCap":51540970},{"date":"2024-10-18","current":-1.327448,"twenty":-2.69392,"median":-1.871334,"eighty":-1.251663,"marketCap":51325767},{"date":"2024-10-25","current":-1.330231,"twenty":-2.68748,"median":-1.868821,"eighty":-1.256738,"marketCap":51433368},{"date":"2024-10-31","current":-1.15769,"twenty":-2.682816,"median":-1.860061,"eighty":-1.249543,"marketCap":44762095},{"date":"2024-11-08","current":-1.282921,"twenty":-2.678751,"median":-1.809791,"eighty":-1.251136,"marketCap":49604148},{"date":"2024-11-15","current":-1.251898,"twenty":-2.674104,"median":-1.720841,"eighty":-1.252073,"marketCap":58642648},{"date":"2024-11-22","current":-1.176095,"twenty":-2.654356,"median":-1.667384,"eighty":-1.249488,"marketCap":55091809},{"date":"2024-11-29","current":-1.171024,"twenty":-2.64274,"median":-1.629813,"eighty":-1.227353,"marketCap":54854273},{"date":"2024-12-06","current":-1.106606,"twenty":-2.639384,"median":-1.600178,"eighty":-1.22448,"marketCap":51836749},{"date":"2024-12-13","current":-1.148018,"twenty":-2.631897,"median":-1.571188,"eighty":-1.222594,"marketCap":53776586},{"date":"2024-12-20","current":-1.167573,"twenty":-2.62396,"median":-1.563013,"eighty":-1.217317,"marketCap":54692620},{"date":"2024-12-27","current":-1.166423,"twenty":-2.616797,"median":-1.547739,"eighty":-1.213926,"marketCap":54638735},{"date":"2025-01-03","current":-1.182527,"twenty":-2.613699,"median":-1.540102,"eighty":-1.211814,"marketCap":55393116},{"date":"2025-01-10","current":-1.304461,"twenty":-2.611376,"median":-1.530098,"eighty":-1.211814,"marketCap":61104858},{"date":"2025-01-17","current":-1.48161,"twenty":-2.609328,"median":-1.528647,"eighty":-1.213041,"marketCap":69403049},{"date":"2025-01-24","current":-1.656458,"twenty":-2.608318,"median":-1.528647,"eighty":-1.213574,"marketCap":77593471},{"date":"2025-01-31","current":-2.167199,"twenty":-2.60789,"median":-1.530098,"eighty":-1.21433,"marketCap":101518124},{"date":"2025-02-07","current":-2.162598,"twenty":-2.593884,"median":-1.54094,"eighty":-1.214734,"marketCap":101302587},{"date":"2025-02-14","current":-1.769189,"twenty":-2.583696,"median":-1.557921,"eighty":-1.214981,"marketCap":82874137},{"date":"2025-02-21","current":-1.863515,"twenty":-2.577932,"median":-1.565558,"eighty":-1.217317,"marketCap":87292655},{"date":"2025-02-28","current":-1.902626,"twenty":-2.570137,"median":-1.584118,"eighty":-1.220574,"marketCap":89124723},{"date":"2025-03-07","current":-1.833607,"twenty":-2.564329,"median":-1.603098,"eighty":-1.220574,"marketCap":85891661},{"date":"2025-03-14","current":-2.672649,"twenty":-2.570137,"median":-1.649192,"eighty":-1.221023,"marketCap":125194918},{"date":"2025-03-21","current":-2.747078,"twenty":-2.60789,"median":-1.669929,"eighty":-1.222594,"marketCap":128681358},{"date":"2025-03-28","current":-2.594838,"twenty":-2.612537,"median":-1.719708,"eighty":-1.224155,"marketCap":121550002},{"date":"2025-04-04","current":-1.679468,"twenty":-2.612537,"median":-1.718575,"eighty":-1.22448,"marketCap":87161019},{"date":"2025-04-11","current":-1.557114,"twenty":-2.610061,"median":-1.684991,"eighty":-1.225254,"marketCap":80811079},{"date":"2025-04-17","current":-1.492618,"twenty":-2.608747,"median":-1.667384,"eighty":-1.226414,"marketCap":77463875},{"date":"2025-04-25","current":-1.557114,"twenty":-2.60789,"median":-1.641927,"eighty":-1.226584,"marketCap":80811079},{"date":"2025-05-02","current":-1.541757,"twenty":-2.60528,"median":-1.62119,"eighty":-1.227308,"marketCap":80014126},{"date":"2025-05-09","current":-1.710675,"twenty":-2.59278,"median":-1.624681,"eighty":-1.230226,"marketCap":88780614},{"date":"2025-05-13","current":-1.695319,"twenty":-2.588663,"median":-1.632359,"eighty":-1.235702,"marketCap":87983660}],"updateTime":1747263985384}}}